A Study of NB004 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-09-26
Target enrollment:
Participant gender:
Summary
This is a Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and
Pharmacokinetics of NB004 in Subjects with Advanced Solid Tumors